Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single-dose hRESCAP PK, safety, and tolerability study in healthy male volunteers
NL-OMON38993Phase 1Active, not recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Jun 2013
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ilofotase alfa in Inflammatory Disorders, rheumatoid arthritis (RA), asthma and 1 more (4 arms), sponsored by Centre for Human Drug Research. Primary endpoints: Safety and tolerability, Pharmacokinetics after microdose administration and 3 more. Started Jun 2013; status: active, not recruiting.
02
Drugs
ilofotase alfa
03
Conditions
Inflammatory Disordersrheumatoid arthritis (RA)asthmamultiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON38993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38993.